Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about multiple recent developments across the company's programs. He highlighted a new manufacturing agreement with CER Groupe, which strengthens Genflow's gene therapy manufacturing capabilities and supports the company's access to research grants in Belgium. "We are lucky to have the possibility to find good quality partners in Belgium," Leire stated.
The company has also made notable progress in intellectual property, securing patent protection in the United States, Europe, and Japan for its Non-Alcoholic Steatohepatitis (NASH) program. Leire explained that these patents enable Genflow to pursue business development opportunities with pharmaceutical partners, offering non-dilutive funding options amid challenging capital markets.
On the clinical front, Genflow selected Exothera as its CDMO after successful large-scale manufacturing tests, which Leire said produced unexpectedly strong yields. This supports faster and more efficient clinical trial preparations while potentially lowering therapy costs.
Leire also provided an update on Genflow's dual gene therapy approach for sarcopenia. The company successfully achieved dual gene expression, which may enhance treatment potency and demonstrates Genflow's capabilities in complex gene therapy design.
Finally, Leire discussed ongoing dog studies in Morocco, which may lead to partnerships in animal health and generate further non-dilutive funding through upfront payments.
For more interviews and company updates, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content.
#GenflowBiosciences #GeneTherapy #Sarcopenia #Biotech #NASH #ClinicalTrials #IPProtection #BusinessDevelopment #AnimalHealth #BiotechnologyNews #NonDilutiveFunding #PharmaPartnership #CDMO
